Lipoprotein(a) : Lp(a)
Background Cardiovascular disease (CVD) and more specifically, Myocardial Infarction (MI) remains a leading cause of morbidity and mortality, despite the targeting of LDL cholesterol via statin therapy.
Download Lipoprotein(a) : Lp(a)
Information
Domain:
Source:
Link to this page:
Related documents
8. Pharmacologic Approaches to Glycemic Treatment ...
care.diabetesjournals.orgEducationregardingmatchingprandial insulin dosing to carbohydrate intake, premeal glucose levels, and anticipated activity should be considered, and se-
Association between Lipid Profile and Liver Function Tests ...
ijpab.comCopyright © August, 2014; IJPAB 26 Association between Lipid Profile and Liver Function Tests in Diabetic Patients
ASE CONSENSUS STATEMENT Use of Carotid Ultrasound to ...
www.asecho.orgASE CONSENSUS STATEMENT Use of Carotid Ultrasound to Identify Subclinical Vascular Disease and Evaluate Cardiovascular Disease Risk: A Consensus Statement from the
An International Atherosclerosis Society Position Paper ...
www.athero.orgPrimary prevention seeks to prevent new onset atherosclerotic cardiovascular diseases (ASCVD). These diseases include coronary heart disease (CHD), stroke, and other
American Association of Clinical Chemistry - LipidCenter
www.lipidcenter.comRecommendations from AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices “LDL-C, non-HDL-C, LDL-P, and total apoB are all, to varying degrees, measures of LDL related risk.”
Major Recommendations for Statin Therapy for ...
www.mplsheart.comGuidance for High-Intensity and Moderate Intensity Statin Dosing High-Intensity Statins • Atorvastatin 40-80 mg • Rosuvastatin 20-40 mg Moderate-Intensity Statins
RXFILES TRIAL SUMMARY WWW JULY 2016; UPDATED MAY …
www.rxfiles.caRXFILES TRIAL SUMMARY WWW JULY 2016; UPDATED MAY 2017 – .RXFILES.CA Page 1 of 3 LEADER: Liraglutide VICTOZA CV Outcomes Trial Summary 1 Liraglutide: Cardiovascular (CV) Outcomes and Mortality in Patients with Type 2 Diabetes (T2DM) In patients with T2DM and at high risk of CV events, does liraglutide reduce CV risk compared to placebo when added to standard care?